Business Context and Reporting Period
Milestone Scientific Inc. (MLSS) is a biomedical technology company developing computer-controlled injection devices for dental and medical markets. The company operates two segments: Dental (CompuDent, STA) and Medical (CompuFlo Epidural System). This Form 10-Q covers the quarter and nine months ended September 30, 2024. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Product Sales | $2,513,805 | $2,059,284 | $6,616,414 | $7,566,848 |
| Gross Profit | $1,836,220 | $1,503,434 | $4,923,526 | $5,282,118 |
| Gross Margin | 73.0% | 73.0% | 74.4% | 69.8% |
| Operating Loss | $(1,469,179) | $(1,506,705) | $(4,714,670) | $(5,126,933) |
| Net Loss | $(1,461,171) | $(1,476,105) | $(2,678,062) | $(5,024,264) |
| Cash & Equivalents (End of Period) | $4,775,597 | $2,170,593 | $4,775,597 | $2,170,593 |
| Working Capital | $6,940,866 | $7,717,756 | $6,940,866 | $7,717,756 |
Note: Working Capital calculated as Total Current Assets ($10,698,651) minus Total Current Liabilities ($3,757,785) as of Sept 30, 2024.
Material Changes vs. Prior Period
- Revenue Trends: Q3 2024 revenue increased 22% year-over-year (YoY) to $2.51M, driven by a 20% increase in Dental sales and a significant rise in Medical sales ($47.4K vs $6K). However, for the nine-month period, total revenue decreased 12.6% YoY to $6.62M, primarily due to a 13.4% decline in Dental sales and the cessation of revenue from China ($0 in 2024 vs $270K in 2023).
- Profitability: The operating loss narrowed slightly in Q3 ($1.47M vs $1.51M) and significantly improved for the nine months ($4.71M vs $5.13M). This improvement was aided by a one-time $1.98M gain on the sale of New Jersey Net Operating Losses (NOLs) recorded in Q2 2024.
- Expense Management: SG&A expenses decreased by $867K for the nine months ended Sept 30, 2024, compared to the prior year, due to reduced salaries, marketing, and warehousing costs. R&D expenses increased by $117K, attributed to the final development stages of the next-generation STA system.
- Liquidity: Cash and cash equivalents increased by $1.8M during the nine-month period, rising from $3.0M to $4.8M. This was driven by the sale of marketable securities ($3.0M) and the NOL sale proceeds, offset by operating cash outflows of $1.4M.
Guidance, Outlook, and Risks
- Outlook: Management forecasts that current cash and liquidity are sufficient to finance operations for at least the next 12 months. The company is actively pursuing positive operating cash flows through increased dental revenue, medical device commercialization, and expense reduction.
- Commercial Milestones: The company secured Medicare Part B physician price assignments in multiple jurisdictions (Florida, Delaware, DC, Maryland, NJ, PA, Arkansas, Colorado, etc.) for the CompuFlo Epidural System. A strategic partnership with Axial Biologics was announced for distribution in NJ, TX, and FL.
- Executive Changes: CEO Arjan Haverhals intends to retire as an officer on December 31, 2024, but will remain as a director and consultant.
- Risks:
- Going Concern: The company has incurred cumulative losses of $126M since inception and requires additional capital to achieve profitability.
- Supply Chain: Reliance on two third-party manufacturers (including a related party, United Systems) creates supply interruption risks.
- Concentration: E-commerce accounted for 53% of net product sales in the first nine months of 2024. One international distributor accounted for 10% of sales.
- Regulatory: Failure to maintain a physical presence in New Jersey for 5 years post-NOL sale could result in a liability of up to $2.2M.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $1.4M operating cash outflow over nine months against the $4.8M cash balance.
- Medical Segment Adoption: Assess the trajectory of Medical revenue growth ($74K for 9M 2024) following recent Medicare price assignments and distribution partnerships.
- China Market Exposure: Confirm the reasons for the complete loss of China revenue ($270K in 9M 2023 vs $0 in 2024) and potential for recovery.
- Related Party Transactions: Review the $1.7M in purchases from United Systems (related party) and the $334K in royalty fees to the Director of Clinical Affairs.
- Inventory Valuation: Note the $1.2M allowance recorded for slow-moving medical finished goods and the total inventory increase to $3.7M.